BidaskClub upgraded shares of Quotient (NASDAQ:QTNT) from a sell rating to a hold rating in a report issued on Saturday, BidAskClub reports.
Other equities analysts have also recently issued reports about the stock. ValuEngine upgraded shares of Quotient from a sell rating to a hold rating in a report on Saturday, October 19th. Zacks Investment Research cut shares of Quotient from a buy rating to a hold rating in a report on Friday, November 8th.
Shares of Quotient stock traded up $0.10 on Friday, hitting $8.32. 385,500 shares of the company traded hands, compared to its average volume of 352,390. The company has a 50-day moving average price of $7.92 and a 200 day moving average price of $9.05. The company has a quick ratio of 3.25, a current ratio of 3.97 and a debt-to-equity ratio of 72.27. Quotient has a 12-month low of $5.73 and a 12-month high of $11.30. The company has a market cap of $552.08 million, a PE ratio of -4.33 and a beta of 0.99.
Quotient (NASDAQ:QTNT) last posted its quarterly earnings results on Monday, November 4th. The company reported ($0.41) EPS for the quarter, missing the consensus estimate of ($0.40) by ($0.01). The firm had revenue of $7.85 million for the quarter, compared to analyst estimates of $6.80 million. Equities research analysts anticipate that Quotient will post -1.58 EPS for the current year.
In other Quotient news, major shareholder Perceptive Advisors Llc acquired 2,500,000 shares of the firm’s stock in a transaction that occurred on Thursday, November 7th. The stock was purchased at an average cost of $7.00 per share, for a total transaction of $17,500,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 14.20% of the company’s stock.
A number of large investors have recently modified their holdings of QTNT. Tower Research Capital LLC TRC boosted its holdings in Quotient by 846.3% in the third quarter. Tower Research Capital LLC TRC now owns 6,738 shares of the company’s stock worth $52,000 after purchasing an additional 6,026 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in Quotient in the second quarter worth $69,000. Cadence Capital Management LLC bought a new stake in Quotient in the third quarter worth $96,000. Northern Trust Corp bought a new stake in Quotient in the second quarter worth $122,000. Finally, Trexquant Investment LP bought a new stake in Quotient in the second quarter worth $123,000. Hedge funds and other institutional investors own 70.62% of the company’s stock.
Quotient Limited, a commercial-stage diagnostics company, develops, manufactures, and commercializes conventional reagent products used for blood grouping in the transfusion diagnostics market worldwide. The company is developing MosaiQ, a proprietary technology platform, which provides tests for blood grouping and serological disease screening.
Read More: What is channel trading?
Receive News & Ratings for Quotient Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quotient and related companies with MarketBeat.com's FREE daily email newsletter.